D. Toppmeyer

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

M. Pegram, Tadeusz Pieńkowski, Donald W. Northfelt et al. · JNCI Journal of the National Cancer Institute · 2004 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17

Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups

Bruce G. Haffty, Doo Ho Choi, Sharad Goyal et al. · Annals of Oncology · 2009 · 69 citations

Medicine, Genetics, Oncology +17

Phase I Clinical and Pharmacologic Study of 13-<i>cis</i>-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies

Robert S. DiPaola, Mohamed M. Rafi, Viral Vyas et al. · Journal of Clinical Oncology · 1999 · 50 citations

Medicine, Oncology, Pharmacology +17

Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene

Jean‐Marc Nabholtz, Tadeusz Pieńkowski, D. Nothfelt et al. · European Journal of Cancer · 2001 · 43 citations

Medicine, Oncology, Pharmacology +16

Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.

Aimin Tan, D. Toppmeyer, Mark N. Stein et al. · Journal of Clinical Oncology · 2011 · 35 citations

Medicine, Oncology, Pharmacology +14